Explore Clinical Trials

2,972 Canadian clinical trials, in plain language.

Recruiting Drug Device Behavioral Older adults Healthy volunteers

Major Depressive Disorder →

23 trials matching “Major Depressive Disorder”

Testing Brenipatide against a placebo for major depressive disorder

Explore this study →

There are 4 groups in this study. Groups A, B and C receive Brenipatide. Group D, the placebo group, receives Placebo.

Sites in Québec, Calgary and 10 more cities

Phase 3
4 groups
Sites in Calgary, Hamilton and 10 more cities
Recruiting

Official title: A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Depressive Disorder, Major · Eli Lilly and Company

Testing Brenipatide against a placebo for major depressive disorder

Explore this study →

There are 4 groups in this study. Groups A, B and C receive Brenipatide. Group D, the placebo group, receives Placebo.

Sites in Québec, Calgary and 7 more cities

Phase 3
4 groups
Sites in Calgary, Kelowna and 7 more cities
Recruiting

Official title: A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

Depressive Disorder, Major · Eli Lilly and Company

Testing Seltorexant against a placebo for major depressive disorder

Explore this study →

There are 2 groups in this study. Group A receives Seltorexant. Group B, the placebo group, receives Placebo, together with one or more of: Seltorexant.

Sites in Kingston and North Vancouver

Phase 3
2 groups
Sites in North Vancouver and Kingston
Recruiting

Official title: A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

Depressive Disorder, Major · Janssen Research & Development, LLC

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches.

Testing NBI-1065845 for major depressive disorder

Explore this study →

Everyone in this study is in one group and receives NBI-1065845.

Sites in North Vancouver and Toronto

Phase 3
1 group
Sites in North Vancouver and Toronto
Recruiting

Official title: Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder · Neurocrine Biosciences

Testing Psilocybin against a placebo for major depressive disorder (MDD)

Explore this study →

There are 2 groups in this study. Group A receives Psilocybin 25 mg. Group B, the placebo group, receives Placebo.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder

Major Depressive Disorder (MDD) · Centre for Addiction and Mental Health

Comparing Oculus VR headset with Ketamine for treatment resistant depression

Explore this study →

There are 2 groups in this study. Group A receives Ketamine, together with one or more of: Oculus VR headset. Group B, the comparison group, receives Ketamine.

One site, in Toronto

Phase 3
2 groups
One site, in Toronto
Recruiting

Official title: InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression

Treatment Resistant Depression · Sunnybrook Health Sciences Centre

Comparing 3 approaches for major depressive disorder

Explore this study →

There are 3 groups in this study. Groups A and B receive Osavampator. Group C receives Placebo.

Sites in Calgary, Kingston and 3 more cities

Phase 3
3 groups
Sites in Calgary, North Vancouver and 3 more cities
Recruiting

Official title: A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder · Neurocrine Biosciences

Testing Psilocybin for treatment resistant depression

Explore this study →

Everyone in this study is in one group and receives Psilocybin 25 mg.

One site, in Toronto

Phase 2
1 group
One site, in Toronto
Recruiting

Official title: Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

Treatment Resistant Depression · Centre for Addiction and Mental Health

Comparing Risperidone with Psilocybin for treatment resistant depression

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Psilocybin 25 mg and Risperidone 1 MG. Group B receives Psilocybin 25 mg.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Treatment Resistant Depression · Centre for Addiction and Mental Health

Testing psilocybin (25 mg) with psilocybin against a placebo for bipolar II depression

Explore this study →

There are 2 groups in this study. Group A receives psilocybin (25 mg). Group B, the placebo group, receives psilocybin 1mg micro-dose.

Sites in Ottawa, Toronto and 1 more city

Phase 2
2 groups
Sites in Vancouver, Ottawa and 1 more city
Recruiting

Official title: Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

Bipolar II Depression · Lakshmi N Yatham

Testing Dextromethorphan-Bupropion for major depressive disorder (MDD)

Explore this study →

Everyone in this study is in one group and receives Dextromethorphan-Bupropion.

One site, in Toronto

Phase 2
1 group
One site, in Toronto
Recruiting

Official title: Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder

Major Depressive Disorder (MDD) · Roger McIntyre

Testing Psilocybin for treatment-resistant depression

Explore this study →

There are 2 groups in this study. Groups A and B receive Psilocybin.

2 sites in Toronto

Phase 2
2 groups
2 sites in Toronto
Recruiting

Official title: Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

Treatment-Resistant Depression · Centre for Addiction and Mental Health

Testing NBI-1065845 against a placebo for major depressive disorder

Explore this study →

There are 2 groups in this study. Group A receives NBI-1065845. Group B, the placebo group, receives Placebo.

Sites in Toronto and Verdun

Phase 3
2 groups
Sites in Toronto and Verdun
Recruiting

Official title: NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder · Neurocrine Biosciences

Testing Apo-levocarb for major depressive disorder

Explore this study →

Everyone in this study is in one group and receives Apo-levocarb.

One site, in Vancouver

Phase 2
1 group
One site, in Vancouver
Recruiting

Official title: Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial

Major Depressive Disorder · University of British Columbia

Testing Escitalopram against a placebo for major depressive disorder

Explore this study →

There are 4 groups in this study. Groups A and C, the comparison group, receive Escitalopram and Brexpiprazole. Groups B and D, the placebo group, receive Escitalopram.

Sites in Toronto, Calgary and 7 more cities

Phase 4
4 groups
Sites in Calgary, Vancouver and 7 more cities
Recruiting

Official title: Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Major Depressive Disorder · Nova Scotia Health Authority

Comparing Ketamine with ECT for treatment resistant depression

Explore this study →

There are 2 groups in this study. Group A receives Ketamine. Group B, the comparison group, receives Ketamine and ECT.

One site, in Saskatoon

Phase 4
2 groups
One site, in Saskatoon
Recruiting

Official title: ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression

Treatment Resistant Depression · University of Saskatchewan

Testing Acceptance and Commitment Therapy with Ketamine for depression - major depressive disorder

Explore this study →

Everyone in this study receives Ketamine and Acceptance and Commitment Therapy.

One site, in Montreal

1 group
One site, in Montreal
Recruiting

Official title: ACT_for Alcohol Use Disorder and Depression

Depression - Major Depressive Disorder · Centre hospitalier de l'Université de Montréal (CHUM)

Testing VLS-01-203 BU against a placebo for treatment resistant depression

Explore this study →

There are 2 groups in this study. Group A receives VLS-01-203 BU. Group B, the placebo group, receives VLS-01-BU Placebo.

Sites in Kingston and Surrey

Phase 2
2 groups
Sites in Surrey and Kingston
Recruiting

Official title: A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

Treatment Resistant Depression · atai Therapeutics, Inc.

Comparing Ketamine hydrochloride with Midazolam Hydrochloride for major depressive disorder

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Ketamine hydrochloride and i-CBT (Internet-based Cognitive Behavioural Therapy). Group B, the comparison group, receives one or more of: i-CBT (Internet-based Cognitive Behavioural Therapy) and Midazolam Hydrochloride.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

Major Depressive Disorder · University Health Network, Toronto

Comparing Cognitive-Behavioural Therapy with Antidepressant medication for depression

Explore this study →

There are 2 groups in this study. Group A receives Cognitive-Behavioural Therapy. Group B receives Antidepressant medication.

Sites in Halifax and Montreal

Phase 2
2 groups
Sites in Halifax and Montreal
Recruiting

Official title: Treatment Interrupts Depression Early

Depression · Nova Scotia Health Authority

Testing Brexpiprazole for bipolar depression

Explore this study →

Everyone in this study is in one group and receives Brexpiprazole.

Sites in Montreal and Hamilton

Phase 3
1 group
Sites in Hamilton and Montreal
Recruiting

Official title: Brexpiprazole Treatment for Bipolar I Depression

Bipolar Depression · Douglas Mental Health University Institute

Comparing Cognitive Behavioral Therapy with Pharmacotherapy for major depressive disorder

Explore this study →

There are 2 groups in this study. Group A receives Cognitive Behavioral Therapy. Group B receives Pharmacotherapy.

One site, in Halifax

Phase 4
2 groups
One site, in Halifax
Recruiting

Official title: Personalized Indications for CBT and Antidepressants in Treating Depression

Major Depressive Disorder · Nova Scotia Health Authority

Comparing Psilocybin with Microcrystalline cellulose for depressive disorder

Explore this study →

There are 2 groups in this study. Group A receives Psilocybin, together with one or more of: Supportive psychotherapy. Group B receives Psilocybin, together with one or more of: Microcrystalline cellulose and Supportive psychotherapy.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: A Randomized Neuroimaging Trial of Psilocybin in Depression

Depressive Disorder · Sunnybrook Health Sciences Centre

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Major Depressive Disorder trials near you.

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.